BR112018006157A2 - derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1 - Google Patents

derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1

Info

Publication number
BR112018006157A2
BR112018006157A2 BR112018006157A BR112018006157A BR112018006157A2 BR 112018006157 A2 BR112018006157 A2 BR 112018006157A2 BR 112018006157 A BR112018006157 A BR 112018006157A BR 112018006157 A BR112018006157 A BR 112018006157A BR 112018006157 A2 BR112018006157 A2 BR 112018006157A2
Authority
BR
Brazil
Prior art keywords
imidazo
pyridine derivatives
dyrk1
dual
clk1
Prior art date
Application number
BR112018006157A
Other languages
English (en)
Inventor
Kotschy ANDRÁS
Bálint BALÁZS
Wéber Csaba
Walmsley David
Humberto CRUZALEGUI Francisco
Sipos Melinda
Frank Burbridge Michäel
Foloppe Nicolas
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of BR112018006157A2 publication Critical patent/BR112018006157A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

a presente invenção refere-se aos compostos de fórmula (i): os quais são úteis no tratamento de câncer, dos distúrbios neurodegenerativos e dos distúrbios metabólicos.
BR112018006157A 2015-09-30 2016-09-30 derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1 BR112018006157A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1559252A FR3041639B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
PCT/EP2016/073395 WO2017055530A1 (en) 2015-09-30 2016-09-30 New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors

Publications (1)

Publication Number Publication Date
BR112018006157A2 true BR112018006157A2 (pt) 2018-10-09

Family

ID=54979755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006157A BR112018006157A2 (pt) 2015-09-30 2016-09-30 derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1

Country Status (26)

Country Link
US (1) US20180273528A1 (pt)
EP (1) EP3356363A1 (pt)
JP (1) JP2018535931A (pt)
KR (1) KR20180054858A (pt)
CN (1) CN108137581A (pt)
AU (1) AU2016333505A1 (pt)
BR (1) BR112018006157A2 (pt)
CA (1) CA2999935A1 (pt)
CL (1) CL2018000783A1 (pt)
CO (1) CO2018003473A2 (pt)
CR (1) CR20180181A (pt)
CU (1) CU20180028A7 (pt)
DO (1) DOP2018000083A (pt)
EA (1) EA201890821A1 (pt)
EC (1) ECSP18023253A (pt)
FR (1) FR3041639B1 (pt)
HK (1) HK1255804A1 (pt)
IL (1) IL258341A (pt)
MA (1) MA43020A (pt)
MX (1) MX2018003860A (pt)
NI (1) NI201800043A (pt)
PE (1) PE20181331A1 (pt)
PH (1) PH12018500650A1 (pt)
SV (1) SV2018005657A (pt)
TN (1) TN2018000090A1 (pt)
WO (1) WO2017055530A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108822103A (zh) * 2018-07-28 2018-11-16 刘凤娟 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用
CN113164476A (zh) * 2018-09-28 2021-07-23 代表亚利桑那大学的亚利桑那校董会 Dyrk1/clk的小分子抑制剂及其用途
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021050824A1 (en) * 2019-09-11 2021-03-18 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2901334A1 (en) * 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors

Also Published As

Publication number Publication date
EP3356363A1 (en) 2018-08-08
AU2016333505A1 (en) 2018-04-19
SV2018005657A (es) 2018-07-31
HK1255804A1 (zh) 2019-08-23
CA2999935A1 (en) 2017-04-06
CR20180181A (es) 2018-06-22
ECSP18023253A (es) 2018-04-30
PE20181331A1 (es) 2018-08-20
KR20180054858A (ko) 2018-05-24
CO2018003473A2 (es) 2018-07-10
IL258341A (en) 2018-05-31
NI201800043A (es) 2018-06-21
PH12018500650A1 (en) 2018-10-01
EA201890821A1 (ru) 2018-10-31
US20180273528A1 (en) 2018-09-27
MA43020A (fr) 2018-08-08
DOP2018000083A (es) 2018-10-15
CU20180028A7 (es) 2018-07-05
FR3041639B1 (fr) 2019-01-25
FR3041639A1 (pt) 2017-03-31
JP2018535931A (ja) 2018-12-06
WO2017055530A1 (en) 2017-04-06
CN108137581A (zh) 2018-06-08
TN2018000090A1 (en) 2019-07-08
MX2018003860A (es) 2018-08-16
CL2018000783A1 (es) 2018-09-21

Similar Documents

Publication Publication Date Title
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
BR112018006157A2 (pt) derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
ECSP16083602A (es) Derivados de quinolina como inhibidores smo
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
EA201790657A1 (ru) Хинолиноновые производные пиридин-2(1h)-она как ингибиторы мутантной изоцитратдегидрогеназы
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
DK2922828T3 (da) 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
BR112016025396A2 (pt) derivados de heterociclil-butanamida
BR112016001645A2 (pt) derivados de oxoquinazolinil-butanamida
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
CR20160133A (es) Derivados de fenilalanina sustituidos
WO2014113407A3 (en) Use of small molecule inhibitors targeting eya tyrosine phosphatase
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
EA202091923A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
EA201691620A1 (ru) Циклопропиламины в качестве ингибиторов lsd1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]